Cuorips Inc. (TYO:4894)

Chimerix Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024
Period Ending	Mar 31, 2025	Mar 31, 2024
Revenue	175	23
Revenue Growth (YoY)	660.87%	-
Cost of Revenue	7	13
Gross Profit	168	10
Selling, General & Admin	423	388
Research & Development	334	209
Operating Expenses	758	598
Operating Income	-590	-588
Interest & Investment Income	4	-
Currency Exchange Gain (Loss)	-36	-
Other Non Operating Income (Expenses)	-18	-41
EBT Excluding Unusual Items	-640	-629
Gain (Loss) on Sale of Investments	-1	1
Asset Writedown	-	-3
Other Unusual Items	-	1
Pretax Income	-641	-630
Income Tax Expense	3	2
Net Income	-644	-632
Net Income to Common	-644	-632
Shares Outstanding (Basic)	8	7
Shares Outstanding (Diluted)	8	7
Shares Change (YoY)	8.69%	-
EPS (Basic)	-80.48	-85.84
EPS (Diluted)	-80.48	-85.84
Free Cash Flow	-892	-474
Free Cash Flow Per Share	-111.47	-64.38
Gross Margin	96.00%	43.48%
Operating Margin	-337.14%	-2556.52%
Profit Margin	-368.00%	-2747.83%
Free Cash Flow Margin	-509.71%	-2060.87%
EBITDA	-514	-518
EBITDA Margin	-293.71%	-
D&A For EBITDA	76	70
EBIT	-590	-588

Source: S&P Global Market Intelligence. Standard template. Financial Sources.